KdT Ventures reposted this
the founding thesis of Terray Therapeutics was that the biggest bottleneck in AI-driven drug discovery is a paucity of high-quality data at scale. five years in, Terray has built an end-to-end platform that integrates automated chemical experimentation and generative AI, all purpose-built with the end (generating safe, effective, drug-like small molecules) in mind. excited to announce a collaboration and investment in Terray from NVentures, NVIDIA's venture arm. Terray and NVIDIA will collaborate on completing SOTA chemistry foundation models, some of which will be made available on NVIDIA's BioNeMo platform for AI in drug discovery. by open-sourcing some of Terray's models, the drug discovery community will see what we see: the "unreasonable effectiveness" of high-quality experimental data in solving complex problems in drug discovery. full press release: https://lnkd.in/e-GkiUCd Eli Berlin Jacob Berlin, PhD Narbe Mardirossian
Congratulations to Patrick Malone, MD PhD and Terray Therapeutics on their collaboration and investment from NVentures, NVIDIA's venture arm!
Patrick Malone, MD PhD congratulations, psyched for the Terray team. Incredible progress in 5 years, cannot wait for the next 5.
Atoms with Consciousness, Matter with Curiosity.
11moIn optimizing and improving the development process of synthetic biology, the various links in the R&D and production chain are separated and disconnected, resulting in low efficiency and extremely low flexibility in product development and delivery, and solving the dilemma of the slow pace of synthetic biology from laboratory to industrialization.